Public health impact and economic benefits of quadrivalent influenza vaccine in Latin America
Open Access
- 24 January 2017
- journal article
- research article
- Published by Taylor & Francis in Human Vaccines & Immunotherapeutics
- Vol. 13 (4) , 877-888
Abstract
Annual trivalent influenza vaccines (TIV) containing 2 A strains and one B lineage have been recommended for the prevention of influenza in most of Latin American countries. However, the circulation of 2 B lineages (Victoria and Yamagata) and difficulties in predicting the predominating lineage have led to the development of quadrivalent influenza vaccines (QIV), including both B lineages. Thus, the objective was to estimate the public health impact and influenza-related costs if QIV would have been used instead of TIV in 3 Latin American countries. We used a static model over the seasons 2010–2014 in Brazil, 2007–2014 in Colombia and 2006–2014 in Panama, focusing on population groups targeted by local vaccination recommendations: young children, adults with risk factors and the elderly. In Brazil, between 2010 and 2014, using QIV instead of TIV would have avoided US$ 6,200 per 100,000 person-years in societal costs, based on 168 influenza cases, 89 consultations, 3.2 hospitalizations and 0.38 deaths per 100,000 person-years. In Colombia and Panama, these would have ranged from US$ 1,000 to 12,700 (based on 34 cases, 13–25 consultations, 0.6–8.9 hospitalizations and 0.04–1.74 deaths) and from US$ 3,000 to 33,700 (based on 113 cases, 55–82 consultations, 0.5–27.8 hospitalizations and 0.08–6.87 deaths) per 100,000 person-years, respectively. Overall, the broader protection offered by QIV would have reduced the influenza humanistic and economic burden in the 3 countries. Despite the lack of local data leading to several extrapolations, this study is the first to give quantitative estimates of the potential benefits of QIV in Latin America.Keywords
This publication has 30 references indexed in Scilit:
- Comparing influenza vaccine efficacy against mismatched and matched strains: a systematic review and meta-analysisBMC Medicine, 2013
- Public health impact of including two lineages of influenza B in a quadrivalent seasonal influenza vaccineVaccine, 2012
- The rationale for quadrivalent influenza vaccinesHuman Vaccines & Immunotherapeutics, 2012
- Comparability of Different Methods for Estimating Influenza Infection Rates Over a Single Epidemic WaveAmerican Journal of Epidemiology, 2011
- Angina frequency after myocardial infarction and quality of life in older versus younger adults: The Prospective Registry Evaluating Myocardial Infarction: Event and Recovery studyAmerican Heart Journal, 2011
- Co-morbidities of COPD in primary care: frequency, relation to COPD, and treatment consequencesPrimary Care Respiratory Journal, 2010
- The need for quadrivalent vaccine against seasonal influenzaVaccine, 2010
- Prevalence and impact of cardiovascular risk factors in Bucaramanga, Colombia: results from the Countrywide Integrated Noncommunicable Disease Intervention Programme (CINDI/CARMEN) baseline surveyEuropean Journal of Preventive Cardiology, 2006
- Effect of comorbidity on coronary reperfusion strategy and long-term mortality after acute myocardial infarctionAmerican Heart Journal, 2006
- Influenza-Associated Hospitalizations in the United StatesJAMA, 2004